KALARIS THERAPEUTICS, INC. (KLRS) Current Ratio
- Current ratio · latest quarter: Value 10.98×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 10.98× | Current assets / current liabilities. $95.92M ÷ $8.74M ≈ 10.98× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 95.92M USD | Assets, Current |
| Current obligations | 8.74M USD | Liabilities, Current |
| Cash and equivalents | 43.17M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 1.12M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $95.92M | $8.74M | $43.17M | (m) | (m) | (m) | $1.12M | (m) | 10.98× |
| 2026-03-31 | $98.47M | $8.08M | $34.43M | (m) | (m) | (m) | $905.00K | (m) | 12.19× |
| 2025-12-31 | $118.81M | $9.71M | $98.05M | (m) | (m) | (m) | $1.28M | (m) | 12.23× |
| 2025-09-30 | $78.18M | $6.07M | $42.39M | $34.61M | (m) | (m) | $494.00K | (m) | 12.89× |
| 2025-06-30 | $91.65M | $7.65M | $88.43M | (m) | (m) | (m) | $3.68M | (m) | 11.98× |
| 2025-03-31 | $102.18M | $7.14M | $100.97M | (m) | (m) | (m) | $2.37M | (m) | 14.31× |
| 2024-12-31 | $2.61M | $24.70M | $1.64M | (m) | (m) | (m) | $1.56M | (m) | 0.11× |
| 2024-09-30 | $122.53M | $1.41M | $116.86M | $5.00M | (m) | (m) | $51.00K | (m) | 86.78× |
| 2024-06-30 | $129.94M | $2.36M | $104.74M | $24.87M | (m) | (m) | $110.00K | (m) | 55.08× |
| 2024-03-31 | $141.48M | $7.66M | $86.04M | $54.49M | (m) | (m) | $765.00K | (m) | 18.48× |
| 2023-12-31 | $187.63M | $28.37M | $90.12M | $93.82M | (m) | (m) | $6.76M | (m) | 6.61× |
| 2023-09-30 | $220.02M | $33.07M | $95.63M | $117.69M | (m) | (m) | $3.92M | (m) | 6.65× |
| 2023-06-30 | $252.91M | $30.56M | $196.95M | $49.58M | (m) | (m) | $5.16M | (m) | 8.28× |
| 2023-03-31 | $212.28M | $24.96M | $115.70M | $86.87M | (m) | (m) | $4.13M | (m) | 8.50× |
| 2022-12-31 | $243.05M | $24.34M | $106.09M | $127.70M | (m) | (m) | $3.00M | (m) | 9.99× |
| 2022-09-30 | $272.04M | $20.72M | $123.83M | $140.27M | (m) | (m) | $4.89M | (m) | 13.13× |
| 2022-06-30 | $176.52M | $21.59M | $71.09M | $101.58M | (m) | (m) | $5.52M | (m) | 8.18× |
| 2022-03-31 | $206.44M | $18.64M | $100.21M | $101.17M | (m) | (m) | $4.47M | (m) | 11.08× |
| 2021-12-31 | $253.35M | $37.85M | $201.66M | $46.46M | (m) | (m) | $8.36M | (m) | 6.69× |
| 2021-09-30 | $281.87M | $24.17M | $243.19M | $32.65M | (m) | (m) | $133.00K | (m) | 11.66× |
| 2021-06-30 | $316.05M | $20.71M | $225.45M | $87.89M | (m) | (m) | $4.20M | (m) | 15.26× |
| 2021-03-31 | $339.66M | $15.50M | $168.65M | $168.35M | (m) | (m) | $2.06M | (m) | 21.91× |
| 2020-12-31 | $361.32M | $12.29M | $122.66M | $233.66M | (m) | (m) | $963.00K | (m) | 29.39× |
| 2020-09-30 | $383.94M | $13.52M | $142.25M | $236.24M | (m) | (m) | $1.84M | (m) | 28.40× |
| 2020-06-30 | $107.29M | $8.91M | $78.27M | $26.18M | (m) | (m) | $680.00K | (m) | 12.03× |
| 2019-12-31 | $127.31M | $9.11M | $61.08M | $64.99M | (m) | (m) | $630.00K | (m) | 13.98× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |